(2)
DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): AGM/EGM
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Announces Nominations to Reappoint Ulrich Dauer as CEO and to Appoint Florian Schmid as CFO
29.01.2021 / 18:09
Vivoryon Therapeutics N.V. Announces Nominations
to Reappoint Ulrich Dauer as CEO and to Appoint Florian Schmid as CFO
HALLE (SAALE) / MUNICH, GERMANY, 29 January 2021 - the Board of Directors (
Board) of Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (
Vivoryon) announced today that it will hold an Extraordinary General Meeting of Shareholders (
EGM) on Friday, March 12, 2021. The EGM will take place virtually.
The EGM agenda, explanatory notes and terms of participation have been made public and are available as of January 29, 2021 on the Vivoryon website https://www.vivoryon.com/extraordinary-general-meeting-2021/. Vivoryon shareholders are invited to consult the company website in order to obtain current information on
Vivoryon Therapeutics N.V. new ISIN code
Search jobs
DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Corporate Action
06.01.2021 / 07:00
Vivoryon Therapeutics N.V. new ISIN code
HALLE (SAALE) / MUNICH, Germany, 06 January 2021 - in connection with the conversion into an N.V., a public company under the laws of the Netherlands (
naamloze vennootschap, N.V. ) which has taken effect on 28 November 2020, Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) announces that the shares will be trading under a new ISIN NL00150002Q7 as from 11 January 2021. The last trading date of the shares under the ISIN DE0007921835 will be 08 January 2021. The ISIN code change will be effected automatically. Trading in Vivoryon Therapeutics shares will not be affected. The central securities depository for the shares under ISIN NL00150002Q7 will be Euroclear Nederland (
DGAP-News: Vivoryon Therapeutics N.V. new ISIN code
vom 06.01.2021, 07:00 Uhr
Bild: pixabay.com
Vivoryon Therapeutics N.V. new ISIN code
06.01.2021 / 07:00
Vivoryon Therapeutics N.V. new ISIN code
HALLE (SAALE) / MUNICH, Germany, 06 January 2021 - in connection with the conversion into an N.V., a public company under the laws of the Netherlands (
naamloze vennootschap, N.V. ) which has taken effect on 28 November 2020, Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) announces that the shares will be trading under a new ISIN NL00150002Q7 as from 11 January 2021. The last trading date of the shares under the ISIN DE0007921835 will be 08 January 2021. The ISIN code change will be effected automatically. Trading in Vivoryon Therapeutics shares will not be affected. The central securities depository for the shares under ISIN NL00150002Q7 will be Euroclear Nederland (
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. new Home Member State
vom 16.12.2020, 07:00 Uhr
Bild: pixabay.com
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. new Home Member State
16.12.2020 / 07:00
Vivoryon Therapeutics N.V. new Home Member State
HALLE (SAALE) / MUNICH, Germany, 16 December 2020 - as a consequence of the conversion into an N.V., a public company under the laws of the Netherlands (
naamloze vennootschap, N.V. ) which has taken effect on 28 November 2020, Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; ISIN DE0007921835) announces that the Netherlands is the home member state of Vivoryon Therapeutics N.V. for the purposes of the implementation of the amended EU Transparency Directive (Directive 2004/109/EC) in Dutch law.
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. new Home Member State
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. new Home Member State
16.12.2020 / 07:00
Vivoryon Therapeutics N.V. new Home Member State
HALLE (SAALE) / MUNICH, Germany, 16 December 2020 - as a consequence of the conversion into an N.V., a public company under the laws of the Netherlands (
naamloze vennootschap, N.V. ) which has taken effect on 28 November 2020, Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; ISIN DE0007921835) announces that the Netherlands is the home member state of Vivoryon Therapeutics N.V. for the purposes of the implementation of the amended EU Transparency Directive (Directive 2004/109/EC) in Dutch law.